|  |
| --- |
| May 22, 2014 |
|  |
| **Contact person specialized press****Michael Klas**Communication, Health & NutritionPhone +49 6181 59-6785Fax +49 6181 59-76785michael.klas@evonik.com |
|  |
| Evonik Industries AGRellinghauser Straße 1-1145128 EssenGermanyPhone +49 201 177-01Telefax +49 201 177-3475www.evonik.de**Supervisory Board**Dr. Werner Müller, ChairmanExecutive BoardDr. Klaus Engel, ChairmanThomas WesselPatrik WohlhauserUte WolfRegistered office EssenRegistered courtEssen local courtCommercial registry B 19474VAT ID no. DE 811160003 |

**Evonik Industries AG announces to raise its price of ThreAMINO® (L-threonine feed grade)**

Essen, Germany - May 22, 2014

The Health & Nutrition Business Unit of Evonik Industries, Germany announces a price increase for ThreAMINO® (L-threonine 98.5% feed grade).

Effective immediately, the company announces a price increase by € 0.30/kg on ThreAMINO**®** (L-threonine feed grade 98.5%) for animal nutrition.

All existing contracts and supply agreements will be honored.

Evonik is the only company worldwide to produce and market the four most important essential amino acids for modern animal nutrition, including MetAMINO® (DL-methionine), Biolys® (source of L-lysine), ThreAMINO® (L-threonine) and TrypAMINO® (L-tryptophan). Evonik provides innovative services and products in over 100 countries, making a valuable contribution to the profitability of its customers, while contributing to healthy, environmentally friendly and sustainable animal nutrition.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.0 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.